Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

15 November 2022

Big pharma not doing enough to improve drug access - analysis

The Access to Medicine Foundation’s CEO, Jayasree K. Iyer, spoke with Reuters journalist Natalie Grover for an article examining the findings of the 2022 Access to Medicine Index, which was published on 15 November.

Direct links

Read the article

The article outlines some of the Key Findings of the 2022 Index, with Jayasree sharing her insights on the progress made by the pharmaceutical industry in addressing access to medicine in low- and middle-income countries (LMICs). However, Jayasree emphasised that this progress largely overlooks sizeable populations in low-income countries.

“If we consistently see that the industry leaves low-income countries behind, then we're never going to solve the problem of access at scale,” she told the outlet.

Reuters also highlighted the fact that only five of the pharmaceutical companies in scope of the 2022 Index are targeting emerging infectious diseases other than COVID-19 – a key finding from the Index that indicates companies are not sufficiently targeting pathogens that could trigger the next pandemic our serious epidemic. 

Read the full article on the Reuters website.  

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved